Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense therapies.

The round was jointly led by China venture capital fund, CICC Qide Fund and the Hillhouse Capital fund GL Ventures and saw participation by SAIC Capital, Everest Venture Capital, Sinopharm-CICC Fund, Shenzhen Co-way, Shanghai Free Trade Zone Fund, Hongtao Capital and other undisclosed investors...